Fig. 2: LPS-induced NF-κB phosphorylation in cDC2 at baseline correlates with response to adalimumab.

a PBMC from psoriasis patients obtained at baseline (week 0, w0) and at w1 and w12 after starting adalimumab therapy were stimulated with either TNF or LPS and NF-κB p65 phosphorylation was measured by phospho flow cytometry. b Correlation analysis between LPS-induced NF-κB p65 phosphorylation (log₁₀FC) in conventional Type 2 DC (cDC2) at w0 and clinical response, expressed as a residual disease at w12 and measured as relative PASI in the discovery cohort (n = 13). Each dot represents one patient. c Violin plot graphs of LPS-induced NF-κB p65 phosphorylation in cDC2 at w0 in PASI75 adalimumab responders PASI (R, blue, n = 7) and non-responders (NR, red, n = 6) *p = 0.035. d Correlation between LPS-induced NF-κB nuclear translocation in DC and LPS-induced NF-κB p65 phosphorylation in cDC2 at w0. e Correlation analyses between NF-κB p65 phosphorylation induced by different stimuli in cDC2 and plasmacytoid Dc (pDC) and residual disease in the PSORT adalimumab combined cohort (n = 25–30). f Representative phospho flow overlay histograms of NF-κB p65 phosphorylation in DC subsets in PASI75 adalimumab responders (blue) and non-responders (red). g Violin plot graphs of NF-κB p65 phosphorylation induced by various stimuli in DC subsets in PASI-75 adalimumab responders (blue, n = 16–20) and non-responders (red, n = 9–10) (p cDC2-LPs = 0.00056, p cDC2-TNF = 0.013, p pDCs-TNF = 0.00034). p values and FDR are reported on the graph in (b), (d) and (e); Mann–Whitney U test (c, g, left and right panels) or unpaired t test (g middle panel). All tests are two-sided. Source data are provided as a Source Data file.